In this study, 13 of 36 different secondary metabolites of Caulerpa (caulerpin, caulerpenyne, 10,11-epoxycaulerpenyne, caulersin, flexilin, racemosin C, racemosin B, caulerprenylol B, caulerprenylol A, monomethyl caulerpinate, α-tocospiro A, α-tocospirone and furocaulerpin) against crucial targets (glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase) for colorectal cancer were carried out by using in-silico pharmacokinetic and pharmacodynamic methods. The gene discussed is G6PD; the disease is colorectal cancer.